Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone with BMS vs Sirolimus-Eluting Stent in Diabetic PCI
NCT00482183Phase 3Completed
- Sponsor
- Showa University
- Start
- Jul 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of pioglitazone in coronary artery disease (CAD) (2 arms), sponsored by Showa University. Primary endpoint: In-stent luminal late loss at 12 months. Started Jul 2003; status: completed.
02
Drugs
pioglitazone
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00482183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482183.